← SynDRA
GANCICLOVIR
SynDRA canonical compound SYN0006444 — structure-anchored drug synonym record
| Clinical phase | Launched |
|---|
| Approval status | Approved · Rx/OTC |
|---|
| Mechanism of action | DNA polymerase inhibitor |
|---|
| Indication | cytomegalovirus (CMV) |
|---|
| Disease area | infectious disease |
|---|
All known targets
- GRM1
- GRM5
- HSV UL30
- TK
- UL26
- VCP
- punA
Mechanisms of action (all sources)
- DNA polymerase inhibitor
- HSV UL30 INHIBITOR
- DNA synthesis inhibitor
Bioactivity evidence (ChEMBL activities table — not curator-asserted)
- DRD2
- MAPK14
- OPRD1
- NR3C1
- NR1I2
- NPY2R
- NPY1R
- NFKB1
- MMP9
- MMP1
- MLNR
- MC5R
- MC4R
- MC3R
- MAPK3
- ACHE
- OPRM1
- MAPK1
- MAOA
- LMNA
- LCK
- KCNH2
- HTR6
- HTR3A
- HTR2C
- HTR2B
- HTR2A
- HTR1A
- HRH3
- HRH2
- OPRK1
- PDE3A
- HMGCR
- SLC22A6
- TK1
- TDP1
- TBXAS1
- TBXA2R
- TACR2
- TACR1
Screening evidence (raw PubChem HTS — uncurated, known false-positive rate)
Drug classes
- DNA Polymerase Inhibitors
- Cytomegalovirus Nucleoside Analog DNA Polymerase Inhibitor
- Nucleoside Analog Antiviral
- Anti-Infective Agents
- Antiviral Agents
- Nucleic Acid Synthesis Inhibitors
ATC classes
- S01A · ANTIINFECTIVES
- J05A · DIRECT ACTING ANTIVIRALS
Cross-references
Synonyms
- CYTOVENE
- GANCICLOVIR SODIUM
- GANZYK-RTU
- VITRASERT
- ZIRGAN
- Zirgan
- denosine
- gancyclovir
- hydroxyacyclovir
- natclovir
- ganciclovir sodium
- Gancyclovir
- BW-759U
- NSC-759656
- RS-21592
- Cymevene
- Cytovene
- Ganzyk-rtu
- Virgan
- Vitrasert
- Vitrasert implant
- Valganciclovir hydrochloride impurity a
- Hydroxyacyclovir
- Ganciclovirum
- HHEMG
- BIOLF-62
- BW 759U
- Ganciclovirum [Latin]
- 2'-NDG
- 2'-Nor-2'-deoxyguanosine
- BW-B 759U
- UNII-P9G3CKZ4P5
- DRG-0018
- BW 759
- CCRIS 9212
- GA2
- Cytovene-IV
Reported adverse events
- Granulocytopenia
- TEN
- Insomnia
- Nausea
- Tremor
- Headache
- Abdominal pain
- Agranulocytosis
- Gastrointestinal disorder
- Anaphylactic reaction
- Injury
- Chills
Look up GANCICLOVIR in the interactive SynDRA portal →